Shire's Veyvondi Set To Grow Europe's VWF Market
Shire's recombinant von Willebrand factor product has gained a positive CHMP opinion and is likely to be drive incremental growth in the company's hemophilia/bleeding franchise, when approved.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.